Notice of Change to the Award Budget for PAR-18-801 "Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44 Clinical Trial Optional)".

Notice Number: NOT-CA-19-055

Key Dates
Release Date: June 18, 2019

Related Announcements
PAR-18-801

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to revise the Award Budget Information for PAR-18-801 "Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44 - Clinical Trial Optional)."

This change will be effective immediately for the next Application due date, which is September 5, 2019.

Part 2. Section II. Award Information

Currently reads:

Award Budget
It is anticipated that projects appropriate to this NCI FOA will qualify for an SBA budget waiver. Therefore, budgets up to $300,000 total costs for Phase I, and up to $2,000,000 total costs for Phase II may be requested.

Modified to Read (in italics):

Award Budget
It is anticipated that projects appropriate to this NCI FOA will qualify for an SBA budget waiver. Therefore, budgets up to $400,000 total costs for Phase I, and up to $2,000,000 total costs for Phase II may be requested.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Ming Zhao, PhD
National Cancer Institute (NCI)
Telephone: 240-276-5225
Email: zhaoming3@mail.nih.gov